Dyne Therapeutics is a clinical stage biotech concern with just over $700 million of cash on its balance sheet. Learn more ...

Repurchasing all convertible note overhang, and - Funding pre-clinical and clinical trials - Management forfeiting $460,000 in accrued payroll BOSTON, MASSACHUSETTS, Jan. 22, 2025 (GLOBE NEWSWIRE) -- ...

The phage therapy market is experiencing significant growth due to the increasing prevalence of antibiotic-resistant infections and the growing interest in alternative treatments. Advances in ...

Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.

A scientific team looks at the progress and challenges in the research and development of brain implants. New achievements in the field of this technology are seen as a source of hope for many ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

Edgewise Therapeutics Inc. (Nasdaq: EWTX) has promoted Behrad Derakhshan, formerly the Boulder-based muscle disease biopharmaceutical company’s chief business officer, to chief operating officer, and ...

Dr. Gehchan brings decades of successful late-stage clinical development and commercial experience to role, further enhancing Kyverna's senior leadership team to execute ...

MoneyShow presents top investment ideas for 2024 from leading advisors. Part 6 includes Medpace Holdings, Ally Financial, ...

Ms. Andor will lead the Company’s expanding Clinical Operations function in support of the ongoing Phase 3 program evaluating ...